NCT06897930 - A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

May 1, 2029

Study Completion Date

May 1, 2029

Conditions

Lupus Erythematosus, Systemic

Interventions

BIOLOGICAL

AZD0120

Single infusion of AZD0120 on visit DAY 1 after completing required lymphodepleting chemotherapy..

DRUG

Cyclophosphamide

Lymphodepletion - specified dose prior to receiving AZD0120

DRUG

Fludarabine

Lymphodepletion - specified dose prior to receiving AZD0120

Trial Locations (5)

RECRUITING

Research Site, New York

NOT_YET_RECRUITING

Research Site, Bethesda

NOT_YET_RECRUITING

Research Site, Seattle

NOT_YET_RECRUITING

Research Site, Seattle

NOT_YET_RECRUITING

Research Site, Syracuse